Commentary: Use it or lose it

Kenji Minatoya, MD, PhD

The advent of thoracic endovascular aortic repair (TEVAR) has completely changed the therapeutic algorithm for thoracic aortic diseases. The benefits of TEVAR are less invasiveness and the rapidity of the procedure. These features are especially helpful in emergent settings. TEVAR could control lethal bleeding rapidly and save the life of the patient in a catastrophic situation.

In this issue of the Journal, Ogawa and colleagues' report endovascular repair of nontraumatic descending thoracic aortic rupture (DTAR). The majority of the patients were treated by open surgery before 2005 and with TEVAR after 2015. Therefore, an accurate comparison between open repair and TEVAR may be difficult. Further, the long-term fate of the lesion treated with TEVAR is unknown due to a rather short follow-up period after TEVAR.

Yet, the surgical outcomes reported by Ogawa and colleagues with TEVAR for nontraumatic DTAR should be congratulated. Perhaps the excellent outcomes can be attributed to their superb techniques, but also to their fine teamwork. A previous report describing endovascular repair of DTAR by Jonker and colleagues indicated 15.2% hospital mortality rate with TEVAR, which is comparable with the current report. Jonker and colleagues stressed the high stroke rate (7.6%) in their report. However, the rate of stroke with TEVAR in the article of Ogawa and colleagues was only 3.8%. In my opinion, this fact indicates that more accumulated know-how of TEVAR for DTAR has improved the outcome.

The study population included 13 aortobronchial fistula (ABFs) or aortoesophageal fistulas. The authors did not describe the procedures of the treatments and the following results minutely; however, TEVAR for ABF is associated with a high risk of recurrence of ABF. Accordingly, TEVAR should be used as a bridge to definitive open repair. Bridging TEVAR to open surgery is also a useful adjunct in patients with aortoesophageal fistula with hemorrhagic shock. The authors described that there was a trend toward increased early and unplanned aortic reintervention in the TEVAR group. The rate of the reintervention was about 20%, and there were several reasons for the reintervention. Yet, the mortality rate in patients requiring unplanned aortic reintervention was 50%. In this point of view, I think early open conversion could be one of the options when initial hemostasis was obtained with TEVAR as the bridge in patients with DTAR.

Although the title of this report indicates the descending aortic rupture, the enrolled population included 12 patients...
with thoracoabdominal aortic aneurysms. TEVAR has been broadly applied to thoracic aortic diseases, but it is more easily applied at the aorta without major branches. TEVAR for thoracoabdominal aortic aneurysm requires additional procedures for the branches. In fact, 4 such cases were treated with TEVAR, and all 3 survivors had chimney/snorkel stent in abdominal branch vessels. Although this kind of high-tech strategy may be a future direction of aortic repair, the long-term results with the new technologies are still obscure, and open conversion from this complicated approach is often difficult.

TEVAR is undoubtedly an excellent procedure to save the patients with DTAR; however, we should not cling to a binary choice and should not make a choice only between TEVAR and open surgery. In my opinion, these 2 major strategies should be combined properly for patients.

References

Commentary: The moment of truth: Longer-term follow-up after endovascular treatment of descending thoracic aortic rupture

Meghana R. K. Helder, MD

Routinely in practice, there is a patient who asks, “Do you still really have to cut me open to fix this?” And the affirmative answer to this question is often couched in questions of the durability of the minimally invasive option. The one place in cardiac surgery that we have moved toward the minimally invasive option being the standard of care is repair of the descending thoracic aorta, especially in times of rupture. The data are quite clear that short-term outcomes are better when these patients are approached with thoracic endovascular aortic repair (TEVAR) instead of open repair. However, the questions that still remain unanswered are whether TEVAR is durable and what is the price to the patient with aortic reintervention.

Ogawa and colleagues must be congratulated in asking the important question of what are the mid-term outcomes of patients who underwent TEVAR for aortic rupture. This study does not include patients with traumatic rupture, which does carry a sicker patient cohort; however, it does limit the generalizability of the paper. The authors have a meaningful average follow-up of 828 ± 1258 days for